Spots Global Cancer Trial Database for gastric adenocarcinoma
Every month we try and update this database with for gastric adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | NCT02485834 | Adenocarcinoma ... Gastric Adenoca... Gastric Cancer | FDG-PET surgery 5-FU capecitabine docetaxel Irinotecan 3D-CRT IMRT | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer | NCT06250075 | Gastric Adenoca... Gastric Cancer Microbiome Cytokines Nutritional Sta... | Formulation wit... Non-interventio... | 18 Years - | Universidade Federal do Amazonas | |
| Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels | NCT04931420 | Metastatic Canc... Foregut Carcino... Gastric Adenoca... Gallbladder Ade... Liver Cancer GI Cancer GI Carcinoma Lung Cancer | Standard of Car... Video-Assisted ... Lobectomy Consolidative R... Ablation Treatm... Resection or Ex... Peritonectomy Transarterial R... | 18 Years - | University of Chicago | |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | NCT02514551 | Gastric Adenoca... Gastroesophagea... | Ramucirumab Paclitaxel | 18 Years - | Eli Lilly and Company | |
| Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | NCT04162665 | Gastric Adenoca... | Adaptive short ... Standard of car... | 19 Years - | Washington University School of Medicine | |
| A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | NCT02340975 | Gastric or Gast... | MEDI4736 + trem... MEDI4736 + trem... MEDI4736 Tremelimumab MEDI4736+tremel... MEDI4736 + trem... | 18 Years - 99 Years | MedImmune LLC | |
| Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. | NCT05102110 | Non Small Cell ... Gastric Adenoca... Pancreatic Canc... Gall Bladder Ca... Bladder Cancer | Oricol Test | 18 Years - 99 Years | Origin Sciences | |
| Durvalumab Long-Term Safety and Efficacy Study | NCT04078152 | Solid Tumor | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Carnoy's Solution Versus Formalin in Rectal and Gastric Cancer Specimens Following: a Randomized Trial | NCT02629315 | Rectal Cancer Gastric Adenoca... | Carnoy's soluti... 10% neutral buf... | 18 Years - 80 Years | Instituto do Cancer do Estado de São Paulo | |
| Klotho _ LRP-6 _ Gastric Adenocarcinoma | NCT05293535 | Gastric Adenoca... Klotho LRP-6 | Prognostic stud... | 18 Years - 80 Years | Assiut University | |
| Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | NCT00848783 | Gastric Cancer Gastric Adenoca... Esophageal Canc... | Irinotecan Cisplatin Surgery Floxuridine Capecitabine | 18 Years - | NYU Langone Health | |
| A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma | NCT06337266 | Gastric Cancer | - | Fujian Medical University | ||
| Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | NCT00464893 | Gastric Cancer Gastric Adenoca... | Catumaxomab catumaxomab | 18 Years - | Neovii Biotech | |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | NCT04150640 | Esophageal Aden... Gastric Adenoca... | Nal-IRI Oxaliplatin 5-FU Trastuzumab Pembrolizumab Nivolumab | 18 Years - | University of Wisconsin, Madison | |
| Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer | NCT00591045 | Stomach Neoplas... Gastric Cancer | mFOLFOX | 30 Years - 70 Years | Peking University | |
| A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma | NCT05008783 | Gastric Adenoca... Gastroesophagea... | AK104 Placebo | 18 Years - 75 Years | Akeso | |
| A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer | NCT02144727 | Gastric Adenoca... | D2 distal subto... D1+ distal subt... | 20 Years - | National Cancer Center, Korea | |
| Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer | NCT00113581 | Esophageal Canc... Gastric Cancer | EMD 72000 (matu... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | NCT02443883 | Gastric Adenoca... Gastroesophagea... | Ramucirumab | 18 Years - | Eli Lilly and Company | |
| Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | NCT01757171 | Gastric Adenoca... Gastroesophagea... Distal Esophage... | Cabazitaxel | 18 Years - | Weill Medical College of Cornell University | |
| Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer | NCT02512380 | Gastric Adenoca... | Docetaxel;oxali... oxaliplatin;s1 | 18 Years - 70 Years | ChineseAMS | |
| Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | NCT03161522 | Gastric Adenoca... Oligometastasis Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... | Capecitabine Chemotherapy Conventional Su... Fluorouracil Radiation Thera... | 18 Years - 79 Years | M.D. Anderson Cancer Center | |
| A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | NCT03802591 | Gastric Adenoca... Gastroesophagea... | CS1001 monoclon... CS1001 placebo Oxaliplatin Capecitabine | 18 Years - 75 Years | CStone Pharmaceuticals | |
| Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | NCT03959293 | Gastric Adenoca... Gastric Cancer | Durvalumab Tremelimumab FOLFIRI Protoco... | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| A Study of LY3435151 in Participants With Solid Tumors | NCT04099277 | Solid Tumor Triple-negative... Gastric Adenoca... Head and Neck S... Cervical Carcin... High Grade Sero... Hepatocellular ... Undifferentiate... Leiomyosarcoma | LY3435151 Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer | NCT05365581 | Gastric Adenoca... Gastroesophagea... Pancreatic Aden... | ASP2138 | 18 Years - | Astellas Pharma Inc | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients | NCT01794026 | Gastric Adenoca... | diffusion weigh... | 18 Years - 75 Years | Bezmialem Vakif University | |
| S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma | NCT02495493 | Gastric Adenoca... | Induction DCS c... | 20 Years - | Yonsei University | |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | NCT03468244 | Advanced Esopha... Gastric Adenoca... Pancreatic Aden... Colorectal Aden... | Personalized mR... | 18 Years - 75 Years | Changhai Hospital | |
| A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | NCT05705635 | Gastric Adenoca... Adenocarcinoma ... | Docetaxel for i... Taxotere | 18 Years - 75 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma | NCT04150640 | Esophageal Aden... Gastric Adenoca... | Nal-IRI Oxaliplatin 5-FU Trastuzumab Pembrolizumab Nivolumab | 18 Years - | University of Wisconsin, Madison | |
| A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | NCT05977998 | Gastric Adenoca... Carcinomatosis | Paclitaxel Dexamethasone Diphenhydramine Famotidine | 18 Years - | M.D. Anderson Cancer Center | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma | NCT00667420 | Esophageal Aden... Gastric Adenoca... | panitumumab, ep... | 18 Years - | Massachusetts General Hospital | |
| Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma | NCT02370849 | Stomach Neoplas... | nimotuzumab cisplatin S-1 | 18 Years - | ChineseAMS | |
| Stomach Cancer Exosome-based Detection | NCT06342427 | Gastric Cancer Gastric Adenoca... Gastric Cancer ... Gastric Neoplas... Gastric Lesion Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer,... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... Gastric Cancer ... | DESTINEX | 18 Years - | City of Hope Medical Center | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer | NCT00113581 | Esophageal Canc... Gastric Cancer | EMD 72000 (matu... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma | NCT03631615 | Gastric Adenoca... | Neoadjuvant che... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02545504 | Gastric Adenoca... | Andecaliximab Placebo Leucovorin 5-fluorouracil Oxaliplatin | 18 Years - | Gilead Sciences | |
| Adjuvant PIPAC in Gastric Cancer Patients | NCT04047004 | Gastric Adenoca... Gastric Cancer | Doxorubicin Cisplatin | 18 Years - | Odense University Hospital | |
| Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma | NCT06123468 | Esophagogastric... | Sacituzumab gov... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | NCT05970627 | Adenocarcinoma ... Adenocarcinoma ... Epstein-Barr Vi... | Toripalimab Oxaliplatin S1 | 18 Years - 80 Years | First Affiliated Hospital of Zhejiang University | |
| Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer. | NCT04850729 | Gastric Adenoca... Gastroesophagea... | non-interventio... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | NCT01178944 | Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate... | Laboratory Biom... Oxaliplatin Pralatrexate | 18 Years - | Roswell Park Cancer Institute | |
| A Study of KK2269 in Adult Participants With Solid Tumors | NCT06266299 | Advanced Solid ... Metastatic Soli... Gastric Adenoca... Gastroesophagea... Esophageal Aden... Non Small Cell ... | KK2269 Docetaxel | 18 Years - | Kyowa Kirin Co., Ltd. | |
| Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma | NCT00964080 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | MBP-426/Leucovo... | 18 Years - | Mebiopharm Co., Ltd | |
| Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | NCT02830594 | Gastric Adenoca... Gastric Squamou... Gastroesophagea... Metastatic Mali... Stage IV Esopha... Stage IV Esopha... | External Beam R... Laboratory Biom... Pembrolizumab | 18 Years - | City of Hope Medical Center | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Assessment of What Patients and Healthcare Providers Value | NCT04483349 | Gastric Adenoca... Pancreatic Aden... Pancreatic Neur... | Survey Administ... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | NCT05977322 | Pancreatic Duct... Gastroesophagea... Glioblastoma Mu... | 68Ga-FF58 177Lu-FF58 | 18 Years - | Novartis | |
| Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. | NCT05687617 | Gastric Cancer Gastric Adenoca... Peritoneal Carc... Peritoneal Meta... | Indocyanine gre... | 18 Years - | Laval University | |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | NCT04344795 | Solid Tumor Colorectal Canc... Non Small Cell ... Squamous Cell C... Urothelial Carc... Endometrial Can... Gastroesophagea... Gastric Adenoca... Solid Tumors Wi... | TPST-1495 twice... TPST-1495 once ... Pembrolizumab | 18 Years - | Tempest Therapeutics | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | NCT02494583 | Gastric Adenoca... | Pembrolizumab Cisplatin 5-FU Capecitabine Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02862535 | Gastric Adenoca... | Andecaliximab S-1 Cisplatin Oxaliplatin Nivolumab | 20 Years - | Gilead Sciences | |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | NCT05567835 | Gastric Adenoca... Gastroesophagea... | Fluorouracil Leucovorin Oxaliplatin Docetaxel GSCF | 18 Years - | Baylor College of Medicine | |
| Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT02545504 | Gastric Adenoca... | Andecaliximab Placebo Leucovorin 5-fluorouracil Oxaliplatin | 18 Years - | Gilead Sciences | |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | NCT03468244 | Advanced Esopha... Gastric Adenoca... Pancreatic Aden... Colorectal Aden... | Personalized mR... | 18 Years - 75 Years | Changhai Hospital | |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | NCT04032704 | Small Cell Lung... Non-small Cell ... Non-small Cell ... Head and Neck S... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Prostate Cancer Melanoma | ladiratuzumab v... pembrolizumab | 18 Years - | Seagen Inc. | |
| Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer | NCT04384601 | Gastric Cancer Neoadjuvant Che... | Chemotherapy | 18 Years - 80 Years | Ruijin Hospital | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma | NCT03631615 | Gastric Adenoca... | Neoadjuvant che... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Assessment of What Patients and Healthcare Providers Value | NCT04483349 | Gastric Adenoca... Pancreatic Aden... Pancreatic Neur... | Survey Administ... | 18 Years - | M.D. Anderson Cancer Center | |
| Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | NCT04034251 | Gastric Adenoca... Gastric Cancer Esophagogastric... Peritoneal Carc... | Paclitaxel Capecitabine BardPort Titani... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma | NCT03788174 | Gastric Adenoca... | Apatinib POF | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05620134 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Melanoma Colorectal Canc... Non-small Cell ... Small-cell Lung... Urothelial Carc... Squamous Cell C... Luminal Breast ... Triple Negative... Clear Cell Rena... Papillary Renal... Gastric Adenoca... GastroEsophagea... Squamous Cell C... Pancreatic Aden... Hepatocellular ... Colorectal Aden... Epithelial Ovar... Thyroid Cancer | JK08 Pembrolizumab | 18 Years - | Salubris Biotherapeutics Inc | |
| This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) | NCT03780608 | Gastric Adenoca... Malignant Melan... | AZD6738 Durvalumab | 19 Years - | Samsung Medical Center | |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer | NCT02333188 | Adenocarcinoma ... Adult Cholangio... Gallbladder Car... Gastric Adenoca... Malignant Gastr... Metastatic Panc... Pancreatic Aden... Stage III Ampul... Stage III Pancr... Stage IIIA Gall... Stage IIIA Gast... Stage IIIB Gall... Stage IIIB Gast... Stage IV Ampull... Stage IV Gallbl... Stage IV Gastri... Stage IV Pancre... | Paclitaxel Albu... Leucovorin Calc... Irinotecan Hydr... Fluorouracil Laboratory Biom... | 18 Years - | University of Chicago | |
| Study of FMT Combined With Nivolumab in Gastric Cancer | NCT05001360 | Gastric Adenoca... Esophagogastric... Esophagus Adeno... | XBI-302 + Nivol... | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer | NCT01283217 | Gastric Adenoca... | DS SP | 20 Years - | Yonsei University | |
| Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. | NCT03773367 | Resectable Gast... | Fluorouracil Oxaliplatin Irinotecan | 18 Years - | Lund University Hospital | |
| Carnoy's Solution Versus Formalin in Rectal and Gastric Cancer Specimens Following: a Randomized Trial | NCT02629315 | Rectal Cancer Gastric Adenoca... | Carnoy's soluti... 10% neutral buf... | 18 Years - 80 Years | Instituto do Cancer do Estado de São Paulo | |
| Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) | NCT05076279 | Gastric Cancer Gastric Adenoca... | Single port or ... | 19 Years - 80 Years | Seoul National University Bundang Hospital | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | NCT04114136 | Melanoma NSCLC Hepatocellular ... Urothelial Canc... Gastric Adenoca... HNSCC Esophageal Aden... Microsatellite ... | Nivolumab or Pe... Metformin Rosiglitazone | 18 Years - | University of Pittsburgh | |
| Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | NCT01379807 | Gastric Adenoca... Gastroesophagea... | panitumumab + d... | 18 Years - | Grupo Gallego de Investigaciones Oncologicas | |
| Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients | NCT01336062 | Gastric Adenoca... | Nanoparticle Al... | 18 Years - 75 Years | Peking University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
